Literature DB >> 16720329

Novel mutations of epidermal growth factor receptor in localized prostate cancer.

Diah A Douglas1, Hong Zhong, Jae Y Ro, Carole Oddoux, Aaron D Berger, Matthew R Pincus, Jaya M Satagopan, William L Gerald, Howard I Scher, Peng Lee, Iman Osman.   

Abstract

We recently demonstrated that EGFR protein overexpression is more common in African American (AA) prostate cancer patients compared to Caucasian patients. We further examine EGFR dysregulation by determining EGFR mutation status in the tyrosine kinase (TK) domain in prostate cancer patients of different ethnicity. Normal and tumor DNA from 89 radical prostatectomy cases were studied for mutations in the EGFR TK domain using genomic DNA sequencing. We identified 4 novel missense mutations in exons 19, 20 and 21 of EGFR TK domain: 3 in Koreans and 1 in Caucasian but none in AA. We also identified 5 distinct synonymous DNA sequence changes, which did not alter the encoded amino acid, in exons 20 and 21 in 31/89 (35%) patients. Interestingly, these synonymous sequence changes were not observed in normal DNA in 7(23%) patients, indicating the presence of de novo somatic mutation to a new synonymous sequence. Our data reveal that EGFR missense mutation in the TK domain occurs in localized prostate cancer. Our data also demonstrate the presence of somatic mutation to a new synonymous sequence in a subset of patients. Larger population-based studies are required to define the association between EGFR mutations and the ethnic background of patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16720329     DOI: 10.2741/1986

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  14 in total

Review 1.  Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review.

Authors:  Lakshmi Chintala; Razelle Kurzrock
Journal:  Mol Oncol       Date:  2010-03-07       Impact factor: 6.603

2.  Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers.

Authors:  Avaniyapuram Kannan Murugan; Jianli Dong; Jingwu Xie; Mingzhao Xing
Journal:  Endocr Pathol       Date:  2011-06       Impact factor: 3.943

Review 3.  Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy.

Authors:  Gur Pines; Wolfgang J Köstler; Yosef Yarden
Journal:  FEBS Lett       Date:  2010-04-11       Impact factor: 4.124

Review 4.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

5.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

6.  Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Authors:  Federica Catalanotti; David B Solit; Melissa P Pulitzer; Michael F Berger; Sasinya N Scott; Tunc Iyriboz; Mario E Lacouture; Katherine S Panageas; Jedd D Wolchok; Richard D Carvajal; Gary K Schwartz; Neal Rosen; Paul B Chapman
Journal:  Clin Cancer Res       Date:  2013-02-26       Impact factor: 12.531

Review 7.  Minireview: the molecular and genomic basis for prostate cancer health disparities.

Authors:  Isaac J Powell; Aliccia Bollig-Fischer
Journal:  Mol Endocrinol       Date:  2013-04-22

Review 8.  The complexity of prostate cancer: genomic alterations and heterogeneity.

Authors:  Lara K Boyd; Xueying Mao; Yong-Jie Lu
Journal:  Nat Rev Urol       Date:  2012-11       Impact factor: 14.432

Review 9.  Molecular basis for prostate cancer racial disparities.

Authors:  Santosh K Singh; James W Lillard; Rajesh Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

10.  Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.

Authors:  Caterina Peraldo-Neia; Giorgia Migliardi; Maurizia Mello-Grand; Filippo Montemurro; Raffaella Segir; Ymera Pignochino; Giuliana Cavalloni; Bruno Torchio; Luciano Mosso; Giovanna Chiorino; Massimo Aglietta
Journal:  BMC Cancer       Date:  2011-01-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.